超敏C反应蛋白对非霍奇金淋巴瘤的预后评估作用

史丽君; 陈林; 周陈姣

doi:10.3969/j.issn.1000-8179.20130176

超敏C反应蛋白对非霍奇金淋巴瘤的预后评估作用

Prognostic evaluation of high sensitivity-C reactive protein in non-Hodgkin lymphoma

摘要

摘要:
目的探讨超敏C反应蛋白（high sensitivity-C reactive protein，Hs-CRP）水平与非霍奇金淋巴瘤（non-Hodgkin lympho- ma，NHL）患者预后的关系。
方法收集85例NHL患者的临床资料，中位随访14（1~59）个月，通过与已知的预后参数进行对比，探讨Hs-CRP对该疾病预后的预测价值。
结果治疗前血清基础Hs-CRP水平≥4 mg/L较Hs-CRP水平 < 4 mg/L患者的无病进展生存期（progression free survival，PFS）更短（P < 0.05），Hs-CRP水平≥4 mg/L较Hs-CRP水平 < 4 mg/L患者的总生存期（overall survi- al，OS）亦更短（P < 0.05）。治疗后早中期Hs-CRP水平与OS、PFS无显著相关性（P>0.05）。Cox多因素分析显示，治疗前血清基础Hs-CRP可作为NHL患者复发以及生存的一个重要预后参数（P < 0.05）。
结论治疗前基础Hs-CRP水平可作为NHL患者预后的一个重要依据。

Abstract:
Objective To investigate high sensitivity-C reactive protein (Hs-CRP) as a prognostic factor in non-Hodgkin lymphoma (NHL).
Methods Data for 85 consecutive non-Hodgkin lymphoma patients were followed up and reviewed to determine the value of Hs-CRP relative to known prognostic parameters.
Results The progression-free survival (PFS) and overall survival (OS) times of patients with pre-therapeutic baseline serum Hs-CRP levels of ≥4 mg/L were shorter than those of patients with basal serum Hs-CRP levels of < 4 mg/L (P>0.05). However, the post-therapeutic, early-to-mid serum Hs-CRP level was not significantly correlated with the OS and PFS times (P>0.05). Multivariate Cox regression analysis showed that the pre-therapeutic baseline serum Hs-CRP level may be an important prognostic parameter for the relapse and survival of NHL patients (P < 0.05).
Conclusion The baseline Hs-CRP level can be a major indicator of prognosis in NHL patients.

HTML全文

参考文献(15)

施引文献

资源附件(0)